Does your body get used to Mounjaro over time?

Do people genuinely stop responding to Mounjaro?

This is the question most people mean when they ask whether the body gets used to tirzepatide. The short answer, based on available trial evidence, is that meaningful weight loss continues well into treatment for most participants. In SURMOUNT-1, published in the New England Journal of Medicine, participants lost weight progressively across a 72-week period at the 10mg and 15mg doses, with no sign of a plateau that would suggest the medicine had simply stopped working.

That said, weight loss does slow as treatment continues, this is expected biology, not failure. As body weight falls, your metabolic rate adjusts downward. Your body defends a new set-point. The medicine keeps appetite suppressed and gastric emptying slowed, but the arithmetic of weight loss changes because your baseline energy needs are lower than when you started. A slowdown is not the same as the medicine wearing off.

Tolerance in the pharmacological sense (where the same dose produces progressively less effect and requires constant escalation) is not what tirzepatide's trial programme demonstrated. The dose titration schedule exists to manage tolerability at the outset, not to compensate for declining efficacy. If you want to understand more about how the medicine works at a biological level, our detailed guide to what Mounjaro does to your body covers the mechanism in detail.

Why do side effects settle, and does that mean the medicine is weakening?

Early in treatment, or after a dose increase, many people notice nausea, burping, constipation or loose stools. These symptoms reflect the medicine doing exactly what it is designed to do: slowing gastric emptying and altering gut-hormone signalling. For most people, these effects are most pronounced in the first one to two weeks at a new dose and then ease considerably.

The easing of GI side effects is often misread as the medicine losing its potency. It is not. Your digestive system has adapted to the new rate of gastric emptying; it is now working with the medicine rather than reacting to it. Appetite suppression, which drives the weight-loss effect, operates through a different pathway and does not diminish in the same way. The NHS tirzepatide page outlines the common side effects and their typical timeline, which is worth reading alongside any personal questions you bring to your prescriber.

One practical note: keeping the pen in the fridge door, in the same spot every week, makes it easier to maintain a consistent injection day, and consistency of dosing matters more than most people realise for stable blood levels of the medicine.

What causes a weight-loss plateau on Mounjaro, and what can be done?

A plateau during treatment is common and has several overlapping causes. Metabolic adaptation, as described above, is one. Gradual relaxation of dietary habits (often unconscious, as initial hyper-vigilance fades) is another. Some people also find that their activity levels have not increased alongside weight loss, which limits calorie deficit. None of these represent the body becoming immune to the medicine.

It is worth reading about how Mounjaro builds up in the body to understand why steady weekly dosing matters for maintaining stable plasma levels. Missing doses or injecting irregularly can produce the very dip in effect that people attribute to tolerance.

If a plateau persists despite good adherence, the right conversation is with your prescriber. Dose titration may be appropriate, or the prescriber may identify a behavioural or physiological factor worth addressing. On the financial side, understanding the change in Mounjaro's UK list price is useful context before committing to a longer treatment course. A clinical review, rather than stopping treatment unilaterally, is nearly always the more productive step.

Does the body get used to tirzepatide differently from other weight-loss medicines?

Tirzepatide's dual mechanism (activating both GIP and GLP-1 receptors) is genuinely different from single-agonist medicines, and there is some research suggesting this dual action may reduce compensatory hunger responses that limit other treatments. Whether this translates to a meaningfully different tolerance profile over years of use is still being studied; the longest robust data currently available runs to 72 weeks.

What is clear is that Mounjaro is not a short-term medicine taken in a burst. The licensed indication frames it alongside sustained dietary change and increased physical activity, and the expectation is continued use for ongoing effect. Some people also wonder whether Mounjaro can make your body ache, which is a question our clinical team is well placed to discuss alongside any other physical changes you notice during treatment. You can find a fuller overview of the medicine's profile on the Mounjaro treatment page. If you are currently experiencing what feels like reduced effect, or you are wondering whether treatment is still right for you, our clinical team at nume (sorry, at our prescribing team) reviews every repeat order individually so these questions can be addressed before the next pen is dispensed. Check your eligibility if you are considering starting treatment for the first time.